EyeGate Pharmaceuticals, Inc.
- Jurisdiction
United States - ISIN
US30233M5031 (EYEG )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
8
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Read full profile
Stock price
Fundamentals
- Net revenue
€13.73M - Gross margin
-0.1% - EBIT
€673.89K - EBIT margin
4.9% - Net income
€7.35M - Net margin
53.5%
Statement period: - (published )
Dividends
- Last dividend amount
-
$0.14 - Ex date
-
- Payment date
-